Status:
COMPLETED
Axillary Reverse Mapping for Invasive Carcinoma of the Breast
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Primary Objectives: * To determine the feasibility of axillary reverse mapping (ARM) in patients undergoing axillary lymph node dissection for breast cancer therapy. * To determine the incidence of b...
Detailed Description
Lymphazurin is a blue dye used usually in breast cancer surgery to trace the drainage pathway that flows to lymph nodes. The dye will travel to the lymph system and will end up in the lymph nodes that...
Eligibility Criteria
Inclusion
- Patients with invasive carcinoma of the breast planning to undergo axillary lymph node dissection at M. D. Anderson Cancer Center.
- Eastern Cooperative Oncology Group (ECOG) performance status of equal to or less than 3.
Exclusion
- Patients with known allergies to blue dye or other contraindications to Lymphazurin.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00645541
Start Date
March 1 2008
End Date
November 1 2010
Last Update
August 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030